🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Ocular Therapeutix, Inc. OCUL R2KR3KPHARMA

Healthcare · Biotechnology · United States
Financial distress score 35/100 (Watch) — see indicators →
https://www.ocutx.com
Company Profile ↓
$6.50
-48.00% 1Y
Mkt Cap$1.43B
P/E-4.64
P/B4.22
52W High$16.11
52W Low$6.29
Book Value$2.37
EPS (TTM)$-1.40

Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 104.0% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Recent Developments

  • Dec 2025 Revenue of $51.95M (-18.5% YoY); net profit $-265.94M.
  • Trailing 12 Months Year-on-year growth — revenue +0.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 104.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:104.00%
1 Year:0.10%

Stock Price Performance

1 Year:-48.00%
6 Months:-31.51%
3 Months:-24.77%
1 Month:-33.81%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 2% of range
$6.29 $16.11
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Death Cross1d ago
  • RSI (14)32.60 · Neutral
Price Performance
1M-33.81%
3M-24.77%
6M-31.51%
1Y-48.00%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 104.0% over 5 years.

CONS

  • Trading 59.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.64
Industry PE
25.45
Forward P/E
-4.47
PEG Ratio
-
Book Value
$2.37
Price to Book
4.22
P/S
42.15
EV/EBITDA
-5.43
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
104.00%
Profit 5Y
-
Revenue (YoY)
0.10%
Earnings (YoY)
-

Profitability & Returns

ROCE
-35.66%
ROE
-72.99%
ROA
-34.95%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.35
EPS (TTM)
$-1.40

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
12.79
Current Ratio
13.11
Debt
$79.38M
Total Assets
$671.32M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.92%
Chg in Prom Hold
-0.01%
FII / Inst Holding
95.30%
Chg in FII Hold
-0.40%

Financial Snapshot

Enterprise Value
$1.43B
Total Revenue (TTM)
$52.05M
EBITDA
$-308.46M
Free Cash Flow
$-159.25M
Operating Cash Flow
$-238.24M
Shares Outstanding
219.62M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 OCUL Ocular Therapeutix, Inc. R2KR3KPHARMA 6.50 -4.64 $1.43B 0.00% -35.66% -72.99% 104.00% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------------340.00K648.00K498.00K504.00K492.00K650.00K829.00K2.26M2.61M1.57M5.88M7.34M11.72M12.15M13.19M12.27M11.96M13.37M15.19M15.08M14.77M16.44M15.43M10.70M13.46M14.54M10.79M13.47M
Operating Income -7.11M-9.63M-11.17M-10.28M-10.51M-11.11M-9.24M-12.47M-15.67M-18.34M-15.20M-12.72M-13.46M-13.56M-14.82M-17.28M-19.66M-21.60M-23.14M-21.40M-16.61M-17.88M-14.01M-20.23M-20.23M-19.53M-17.83M-19.92M-21.54M-22.55M-20.57M-19.21M-31.62M-43.59M-46.00M-63.92M-67.64M-68.70M-93.34M-82.11M
Net Income -7.58M-10.01M-11.52M-10.64M-10.84M-11.45M-9.60M-12.82M-16.02M-18.69M-15.57M-13.10M-13.77M-13.80M-15.01M-17.40M-17.12M-24.45M-18.78M-26.02M-21.51M-36.57M-11.94M3.12M-8.48M2.66M-12.54M-18.77M-24.19M-30.32M-20.68M-516.00K-64.85M-43.78M-36.49M-64.05M-67.81M-69.42M-88.61M-78.76M
Diluted EPS -------------0.40-0.37-0.38-0.42-0.45-0.57-0.45-0.53-0.41-0.64-0.21-0.24-0.25-0.23-0.22-0.25-0.31-0.39-0.26-0.25-0.49-0.26-0.22-0.38-0.39-0.38-0.40-0.35
R&D Expense 4.72M6.74M8.26M-7.07M6.98M5.69M-6.73M8.12M8.13M-8.23M8.74M9.69M-11.32M9.41M10.23M-6.10M8.02M6.95M10.93M13.86M12.72M13.10M13.10M13.72M14.75M15.09M15.02M20.73M28.86M37.05M42.86M51.08M52.36M66.21M54.14M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 10.00K-772.00K1.75M1.89M1.92M1.99M4.23M17.40M43.52M51.49M58.44M63.72M51.95M
Operating Income -13.67M-12.90M-27.09M-38.20M-43.33M-61.92M-59.12M-85.80M-62.85M-78.04M-78.65M-82.38M-171.78M-270.02M
Net Income -14.09M-13.32M-28.65M-39.75M-44.70M-63.39M-59.98M-86.37M-155.64M-6.55M-71.04M-80.74M-193.51M-265.94M
Diluted EPS --------1.91-2.56-0.98-0.97-1.02-1.22-1.42
R&D Expense 11.54M10.52M18.88M26.61M27.07M30.88M36.91M41.09M28.69M50.08M53.46M61.05M127.64M197.10M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --19.15M78.19M110.31M74.94M55.43M73.04M78.74M261.86M204.89M149.29M252.06M457.94M808.06M
Total Equity -32.73M-46.61M-59.47M58.70M89.59M52.01M26.15M35.88M-3.63M76.09M88.00M35.38M91.13M315.34M654.31M
Cash & Equivalents 5.33M23.85M17.50M37.39M30.78M32.94M41.54M54.06M54.44M228.06M164.16M102.30M195.81M392.10M737.06M
Total Liabilities --4.27M19.50M20.72M22.93M29.28M37.17M82.37M185.77M116.89M113.91M160.93M142.59M153.75M
Current Liabilities --3.34M5.87M5.38M8.30M13.43M9.16M12.03M26.66M26.34M31.39M34.90M41.35M50.81M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----33.74M-34.00M-50.47M-49.23M-77.58M-53.55M-65.55M-59.60M-70.23M-134.68M-204.88M
Investing Cash Flow ----38.57M37.07M26.95M-1.89M-2.24M-841.00K-1.19M-3.71M-6.09M-1.29M-11.88M
Financing Cash Flow ---65.70M585.00K32.01M68.64M75.34M228.01M2.85M1.45M169.83M332.11M561.72M
Capital Expenditure -203.00K-387.00K-1.26M-1.78M-1.92M-8.25M-1.89M-2.24M-841.00K-1.19M-3.71M-6.09M-1.29M-12.01M
Free Cash Flow ----35.52M-35.92M-58.73M-51.12M-79.82M-54.40M-66.74M-63.32M-76.32M-135.97M-216.89M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------
Operating Margin % -136,710.0%--3,509.6%-2,182.7%-2,296.0%-3,220.1%-2,970.8%-2,029.9%-361.1%-179.3%-152.7%-141.0%-269.6%-519.8%
Net Margin % -140,930.0%--3,710.9%-2,271.3%-2,369.0%-3,296.2%-3,014.0%-2,043.3%-894.3%-15.1%-138.0%-138.1%-303.7%-511.9%
ROE % 30.2%22.4%-48.8%-44.4%-86.0%-242.4%-167.2%2,379.4%-204.5%-7.4%-200.8%-88.6%-61.4%-40.6%
ROCE % --81.6%-37.5%-36.4%-65.0%-147.4%-92.5%-128.6%-26.7%-43.7%-66.7%-37.9%-41.2%-35.7%

Shareholding Pattern

Insiders
0.92%
Institutions
95.30%
Public Float
96.18%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 14.96% 32.84M $247.64M
2 Deep Track Capital, Lp 8.96% 19.69M $148.43M
3 Blackrock Inc. 8.82% 19.38M $146.10M
4 Avoro Capital Advisors LLC 5.71% 12.54M $94.55M
5 Summer Road LLC 5.56% 12.21M $92.05M
6 Venrock Adviser, LLC 4.71% 10.35M $78.02M
7 Vanguard Capital Management LLC 4.02% 8.83M $66.60M
8 Price (T.Rowe) Associates Inc 3.47% 7.62M $57.48M
9 Logos Global Management LP 2.41% 5.30M $39.96M
10 State Street Corporation 2.38% 5.23M $39.46M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OCUL

Google News Fri, 23 Oct 2026

Ocular Therapeutix, Inc. Estimates – NASDAQ:OCUL - TradingView

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE8wdVJnNEpEeTRqRTNpWEhNckZMYVk2TENpTmpEbDBfb1lhY3VKRm5OeVd6X2c4ZWhXdW1VbktMTURxdXNKdVhfYUFOWC11ZURoSXJmWnN2cFF3SVpBdTRmVEMwT2RuNkFuUTI0M2xHZG9lMTE5cTNaZw?oc=5" target="_blank">Ocula…

Google News hu, 01 Oct 2026

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQdnFJTzVhYzBVYWdjQWlKNzVJUGJHTFpmRHRrZ19FOUJLckJBMkwtZEFoME5NSGtrZ1BMTW04VjlzanVPM0RvZ3JDNl9rdmhrVEdBQVNSSE44aFE0dTlfOHQyNEg4WkdlVjE4NUlQRFBGV293eWJYX3BTeUNtVm9JTllHS01vX3VEME5Hdz…

Google News hu, 01 Oct 2026

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNS3JvMDFubXJKQUI2ODRUd1ZIR19iYlR4ZU15Y0tUVzAtREhxSkRtZHByUEFzVW04M0NWclh2MmF0RGU4YXE3aDZ0TUJDVzByUnBmM0p2YVl2d2hSSnpXSU5RRkREZEpvVzRXWjlNX0NQODNXMUFZMmFpZ0tBSXhhbklta0ZOSUs2Sk9POT…

Google News Wed, 21 Oct 2026

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA) - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxOVnF3TzBvRkVvNkt4ZFh4Z1QxNTFVLUdndXE2YkhnZDFQMzU0VlZkTDNKYXNkSjBJeUtUNXk0QjBZM2U5YVQ0U0RzU0U4c2xhcTI1N0hKOWlMYzJJTUdvaExTTXc3bzJxejlHYV9mVUx2ZHlHQzhkWlhxTzhQbk83SDRUV1hUS3g5T3lZbT…

Google News ue, 20 Oct 2026

Ocular Therapeutix (OCUL) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxObUQySGE0TEJRSXprelhrN0pvd0h4akZia1FqNl9ydmNmMUFSajhNdG5qS2JFVnYwVVJzUWZxaHhkdFpkMGNTYzdfWTliOEJkY2dkdWd2UjM0N1ppQWZaVnRjNlh1ek1GMmh4WFg5OGFoa3NGX2FrdVNKQ3RuYmZkdS05MC0xcjRER3Exak…

Google News Fri, 23 Oct 2026

OCUL Jan 2029 12.000 call (OCUL290119C00012000) interactive stock chart - Yahoo Finance Australia

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE0waXllNVpuVjQ4SG1ZNkhtNzRrSGx4cktaVHUzcTQtOFRfeUdMWjEtS0tRR0RXTElzQWZzTjBVMnVYZDZVSU5XMmpubFR2SjZnaGRNTENnS1FIOE1xTlJCbmNGY1k4cGh2QWNsUU5B?oc=5" target="_blank">OCUL Jan 2029 12.00…

OCUL — Frequently Asked Questions

What is the current share price of Ocular Therapeutix, Inc. (OCUL)?

As of 2026-10-23 16:27 PDT, Ocular Therapeutix, Inc. (OCUL) trades at $6.50 on NasdaqGM. Its 52-week range is $6.29 to $16.11.

What is the market capitalisation of OCUL?

Ocular Therapeutix, Inc. (OCUL) has a market capitalisation of $1.43B on NasdaqGM.

What is the P/E ratio of OCUL?

OCUL trades at a trailing price-to-earnings (P/E) ratio of -4.64. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 4.22.

What is the return on equity (ROE) of OCUL?

OCUL has a return on equity (ROE) of -72.99%. Its return on capital employed (ROCE) is -35.66%.

Is OCUL a good stock to buy?

This page provides a data-driven analysis of Ocular Therapeutix, Inc. (OCUL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space